Search clinical trials for: cetuximab

Total 1021 results

Merck KGaA, Darmstadt, Germany

Completed

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck (CHANGE)

Squamous Cell Carcinoma of the Head and Neck

China, Korea, Republic of
Merck KGaA, Darmstadt, Germany

Completed

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Colorectal Neoplasms

Korea, Republic of
Western General Hospital, Australia
Merck Serono International SA; Alchemia Oncology

Unknown

Trial of FOLF(HA)Iri With Cetuximab in mCRC (Chime)

Metastatic Colorectal Cancer

Australia
Merck KGaA, Darmstadt, Germany

Completed

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Head and Neck Cancer

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

Colorectal Cancer

United States
Centre Oscar Lambret

Unknown

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Epidermoid Head and Neck Cancer

France
Merck KGaA, Darmstadt, Germany

Completed

Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) (OPUS)

Neoplasm Metastasis | Colorectal Cancer

France, Italy, Poland, Russian Federation, Spain, Germany, Austria, Belgium, Israel, Romania, Greece, Ukraine, Portugal
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Terminated

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Head and Neck Cancer

France, Russian Federation, Spain, United Kingdom, Germany, Hungary, Poland, Ukraine, Austria, Netherlands, Slovakia, Sweden, Switzerland, Belgium, Italy, Portugal, Czech Republic
Merck KGaA, Darmstadt, Germany

Completed

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (EXPAND)

Gastric Cancer

Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, Germany, China, Hungary, Romania, Japan, Hong Kong, Argentina, Austria, Belgium, Chile, Israel, Greece, Taiwan, Au... and more
GlaxoSmithKline

Completed

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Neoplasms, Breast

Poland, Russian Federation, Latvia, Romania
Dartmouth-Hitchcock Medical Center

Completed

Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer

Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
Choice Pharma Taiwan

Completed

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

Carcinoma, Squamous Cell of Head and Neck

Taiwan
Merck KGaA, Darmstadt, Germany

Withdrawn

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Neoplasms, Squamous Cell
National Center for Tumor Diseases, Heidelberg

Terminated

Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer (GastroLap)

GastroEsophageal Cancer

Germany
Merck KGaA, Darmstadt, Germany

Completed

Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. (FUTURE)

Previously Untreated Metastatic Colorectal Cancer

France, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
Boehringer Ingelheim

Completed

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
Merck KGaA, Darmstadt, Germany

Terminated

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

France
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Renal Cell Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Metastatic Squamous Neck Cancer With... and other conditions

United States
The Christie NHS Foundation Trust
Merck Sharp & Dohme LLC

Completed

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy (eSCOUT)

Metastatic Colorectal Cancer

United Kingdom
State University of New York at Buffalo

Withdrawn

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

Opiate Addiction

United States
National Cancer Institute (NCI)

Completed

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
National Cancer Institute (NCI)

Terminated

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Liver Metastases | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Eli Lilly and Company

Completed

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Head and Neck Neoplasms

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Regione Lombardia
Mario Negri Institute for Pharmacological Research; Istituto Clinico Humanitas and other collaborators

Completed

Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.

Colorectal Cancer

Italy
Merck KGaA, Darmstadt, Germany

Completed

A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment

Metastatic Colorectal Cancer

Taiwan
Merck KGaA, Darmstadt, Germany

Completed

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) (NEXT)

Non-Small Cell Lung Cancer (NSCLC)

Germany
Technical University of Munich

Unknown

Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer

Esophageal Cancer

Germany
Merck KGaA, Darmstadt, Germany

Completed

Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (ADVANTAGE)

Squamous Cell Cancer

France, Italy, Spain, Germany, Hungary, Austria, Switzerland, Belgium, Poland
Wolfgang Hilbe
Sanofi; Merck Sharp & Dohme LLC; TAKO - Tiroler Arbeitskreis Onkologie

Completed

Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-small-cell Lung

Austria
National Cancer Institute (NCI)

Completed

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage III Colon Cancer | Stage III Rectal Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Cell Carcinoma of the Head and Neck

Japan
University of Chicago
Bristol-Myers Squibb

Terminated

Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Jiangsu Cancer Institute & Hospital

Completed

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Centre Jean Perrin
Sanofi; Merck Sharp & Dohme LLC

Completed

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Breast Cancer

France
Massachusetts General Hospital
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical... and other collaborators

Completed

Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Gynecologic Oncology Group
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Cancer

United States
PD Dr. med. Volker Heinemann
Merck KGaA, Darmstadt, Germany

Unknown

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Neoplasm Metastasis | Colorectal Cancer

Germany
Merck KGaA, Darmstadt, Germany

Completed

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Carcinoma of the Head and Neck

Japan
Gynecologic Oncology Group
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Norway, Canada, Australia, Japan
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer (BALI-1)

Breast Neoplasm

Spain, United Kingdom, Germany, Australia, Austria, Belgium, Israel, New Zealand, Portugal, Italy, Ireland
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

Head and Neck Cancer

United States
Merck KGaA, Darmstadt, Germany
Merck Serono Limited, UK

Completed

A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice (RESECT)

Metastatic Colorectal Cancer

United Kingdom
University of Colorado, Denver

Completed

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

Recurrent Head and Neck Cancer

United States
Heinrich-Heine University, Duesseldorf

Completed

Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (ACCRA-HN)

Head and Neck Cancer

Germany
National University Hospital, Singapore

Unknown

A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab

Rectal Cancer

Singapore

Search clinical trials for: cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations